Financing led by psychedelic investment fund Negev Capital and leading functional mushroom manufacturer Nammex VANCOUVER, BC, July 13, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, is pleased to announce that, further to its news release dated June 30, 2022…


Previous articleNuminus Wellness Inc. Reports Q3 2022 Results
Next articleSmall Pharma Reports Fiscal First Quarter 2023 Highlights